 Early, Promising Data from Physician-Led Phase 2 Open Label Clinical Trial Support XEN007 as a Potential Treatment of Childhood Absence Epilepsy CAE Early, Promising Data from Physician-Led Phase 2 Open Label Clinical Trial Support XEN007 as a Potential Treatment of Childhood Absence Epilepsy CAE 